At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 20 enrolled
Drug / intervention
Sirolimus +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Sirolimus in Conjunction With EYLEA® (Aflibercept) Versus EYLEA® Alone for Exudative AMD
In Brief
A Phase 2 clinical trial evaluating Sirolimus and EYLEA for Exudative Age Related Macular Degeneration. Completed, enrolled 20 participants across 1 site.
Detailed Summary
To determine safety and efficacy of intravitreal injections of Sirolimus with adjunct EYLEA in subjects with exudative age related macular degeneration (AMD) with persistent intraretinal or subretinal edema due to neovascular AMD despite previous intravitreal anti-vascular endothelial growth factor (antiVEGF) treatment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartApr 2016
First PostedApr 2016
Primary CompletionMar 2017
Study CompletionApr 2017
TodayJul 2026
First PostedApr 11, 2016
Enrollment StartApr 1, 2016
Primary CompletionMar 20, 2017
Study CompletionApr 4, 2017
TodayJul 2, 2026
Enrollment to primary: 12 monthsPosted 10.2 years ago
Interventions
Sirolimusdrug
EYLEAdrug